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Abstract 
Introduction: Headache is the most common neurologic symptom among referees to the emergency department 
(ED), while the best treatment has not yet been found. Therefore, in the present study pain relief effects of meto-
clopramide and acetaminophen were compared in patients suffered acute primary headache. Methods: This study 
was a double-blind randomized clinical trial performed in Imam Khomeini Hospital, Urmia, Iran, through July to 
October 2014.  All adult patients, with acute primary (migraine, tension type and cluster) headache referred to the 
ED were included in this study. Pain severity was measured with 10 centimeters numeric rating scales. The patients 
were randomized into two groups of intravenous (IV) metoclopramide (10 milligrams) and acetaminophen (1 
gram). Pain score, success rate, and drug complications were compared between the 2 groups at 0, 15, 30, 60, and 
120 minutes after injection. Results: 100 patients were equally categorized into two groups (mean age of 32 ± 13.2 
years; 51.2% male). Initial pain score in metoclopramide and acetaminophen groups were 9.1 and 9.4, respectively 
(p = 0.46). IV metoclopramide did not have any analgesic effect at 15 minutes, but had good effect at 30 minutes. 
While, the analgesic effect of acetaminophen initiated after 15 minutes. After 2 hours, both drugs had good thera-
peutic effect on primary headaches (p < 0.001). Conclusion: The present study demonstrated that efficacy of meto-
clopramide for pain relief in primary headaches is lower than acetaminophen.  In this regard, success rate of acet-
aminophen was 42.0% versus 0% for metoclopramide within 15 minutes. The efficacy of acetaminophen continued 
until 60 minutes. 
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Introduction: 
Headache is one of the most common neurologic 
symptoms among patients admitted to the emer-
gency department (ED), as 3 million patients are 
annually visited only in the EDs of United States (1, 2). 
The disease is categorized into primary (such as mi-
graine, tension type, and cluster) and secondary (such as 
those following intracerebral hemorrhage, trauma, tu-
mor, etc.) groups. Primary is the most frequent type seen 
in EDs and 90% of them include migraine, tension, or 
even a combination of them (3, 4). Approximately, 12% 
of general population suffer from migraine and acute ex-
acerbations cause severe and disabling disorders (5-7).  
Several agents such as nonsteroidal anti-inflammatory 
drugs (NSAIDs), opioids, antiemetics, antipsychotics, etc. 
have been used for treatment (8). Recently, the use of do-
pamine antagonists, such as metoclopramide (alone or 
in combination with other drugs), and serotonin ago-
nists, like sumatriptan, for this purpose has increased (9, 
10). Administration of metoclopramide relieves the in-
tensity of headaches; however, its efficacy varies among 
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ceptable therapeutic effect for  metoclopramide in pri-
mary headaches, Coppola et al. deemed its efficacy to be 
equal to placebo (4, 11, 12). Given the above results, 
evaluation of metoclopramide’s efficacy in management 
of primary headaches requires more studies to derive a 
concrete and clear conclusion. Therefore, the present 
study aimed to compare analgesic effects of intravenous 
(IV) metoclopramide and acetaminophen for acute pri-
mary headaches. 
Methods: 
Study design and setting 
This study was a double-blind randomized clinical trial 
performed in Imam Khomeini Hospital, Urmia, Iran, 
through July to October 2014.  The effect of IV metoclo-
pramide (10 milligrams) and acetaminophen (1 gram) in 
treatment of acute headaches was compared. For ethical 
reasons, there was no placebo arm. The study protocol 
was confirmed by Ethical Committee of Urmia University 
of Medical Sciences and informed consent was obtained 
from patients. This protocol was registered in Iranian 
Registry of Clinical Trials with IRCT Number: 
IRCT2014081817812N3. 
Subjects 
Patients with acute primary headache and pain severity 
over 4 based on numeric rating scale (NRS), who were 
referred to the ED and did not have any systematic dis-
ease, were included. Exclusion criteria were having al-
lergy to metoclopramide and acetaminophen, hepatic 
failure, secondary headache, pregnancy, breast-feeding, 
renal insufficiency, arbitrary treatment, and the case of 
recurrent headache. Migraine, tension type, and cluster 
headaches were diagnosed based on International Head-
ache Society’s International Classification of Headache 
Disorders (ICHD) criteria (13). 
Intervention 
The patients were randomized into two groups of meto-
clopramide (intervention group) with dosage of 10 mil-
ligrams, IV, in 2 minutes and acetaminophen group (con-
trol group) with dosage of 1 gram, slow IV, in 10 minutes. 
Randomization was performed by block randomization 
(size of 5 for blocks), using an online random number 
generator (RNG). Solutions were prepared by an inde-
pendent pharmacist and kept in a sealed envelope. Drugs 
were injected by a physician blinded to the studied 
groups. Response to treatment and the side effects were 
assessed within 15, 30, 60, and 120 minutes after receiv-
ing medications and then compared with the baseline. 
The ED staff were blinded to composition of solutions 
and studied groups. The data of the prescribed solution 
were only available for the staff when drug complica-
tions and other adverse effects appeared in patients and 
the patient was excluded from the study. Rescue dose 
was prescribed, if the pain continued after 30 minutes 
from first drug administration. The disclosure of the data 
about the prescribed medicine(s) was not required dur-
ing the study period.  
Measurements 
11-scale standard numeric rating scale (NRS) was used 
to assess the pain score of patients (14). Patients were 
given a score number between 0 and 10, 0 representing 
no pain and 10 demonstrating the worst conceivable 
pain. Pain severity was assessed in the baseline (admin-
istration time) and then reassessed 15, 30, 60, and 120 
minutes after medication. This follow up was performed 
because 120 minutes is a more standard endpoint for 
outpatient migraine trials (15). Nausea, vomiting, ver-
tigo, and lethargy were recorded as adverse effects 
based on self-reports and clinical manifestations. Thera-
peutic success rate was defined as decreasing pain score 
to at least 3.   
Statistical analysis      
The minimum required sample size for the present study 
considering the clinically significant change of 2 scores 
in pain severity, standard deviation of 2.7 and 1.2 centi-
meters for  effects of metoclopramide and acetamino-
phen in decreasing headache,  power of 90% (β=0.1) and 
the error rate of 5% (α=0.05) was estimated to be 33 
subjects (16, 17).  
Data were analyzed using SPSS 21. Quantitative varia-
bles were reported as mean and standard deviation and 
qualitative ones as frequency and percentage. Chi-
square and Fisher exact tests were also used for compar-
ison of basic characteristics of the two groups. Because 
data was not normally distributed, the comparison be-
tween pain severity changes in patients was performed 
using Wilcoxon-rank test. The success rate was reported 
as frequency and percentage as well as comparison of 
time changes between two therapies performed by non-
parametric test for trend, which is an extension model of 
the Wilcoxon rank-sum test.  Since some basic features 
between two therapeutic groups had significant differ-
ence, general linear model was done to find if success 
rate had significant difference after moderating these 
factors. P < 0.05 was considered as a significant level. 
Results: 
 100 patients were equally categorized into two groups of 
IV acetaminophen and metoclopramide (mean age of 32 ± 
13.2 years; 51.2% male). Table 1 shows demographic data 
of patients. As can be seen, age distribution of the two 
groups was significantly different (p < 0.001).  Most mi-
graine sufferers received IV acetaminophen, while patients 
with tension headache mostly took metoclopramide (Table 
1, p < 0.001). The pain severity at administration time had 
no difference between the groups (p = 0.46). However, the 
mean pain severity at 15 minutes after taking acetamino-
phen was significantly less than metoclopramide group 
(7.0 ± 1.4 versus 9.0 ± 1.3, p < 0.001). This pattern was seen 
within 30 minutes (4.5 ± 2.0 versus 6.6 ± 1.5; p < 0.001), 60 
minutes (3.1 ± 2.1 versus 5.4 ± 1.6; p < 0.001), and even 120 
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minutes (3.6 ± 2.0 versus 1.5 ± 1.2; p < 0.001) after injection 
(Table 2).   
21 (42%) patients in acetaminophen group had signifi-
cant pain relief, while none of subjects in metoclo-
pramide group had such effectiveness in 15 minutes af-
ter medication. The 30-minute success rate for aceta-
minophen and metoclopramide groups were 100% and 
74%, respectively. 100% therapeutic success rate in IV 
acetaminophen remained until 120 minutes (Table 2, p 
= 0.001). No side effect was seen among patients. Only 3 
(6%) patients of metoclopramide group needed the res-
cue dose.  After adjustment of analysis for basic charac-
teristics, the rate of therapeutic success for IV aceta-
minophen at 15 minutes (OR=1.43; 95% Cl=1.2-1.7; p < 
0.001), 30 minutes (OR=1.38; 95%Cl=1.17-1.64; p < 
0.001), and 60 minutes (OR=1.10; 95% Cl=1.01-1.26; p = 
0.04) was more than metoclopramide (Table 3). 
Discussion: 
Based on the present study and similar to other major 
studies, metoclopramide had a pain relief effect on pri-
mary headaches, but in contrast to other researches, 
here metoclopramide had inferior effect to acetamino-
phen. It can be justified under racial differences. Several 
studies have been performed regarding therapeutic ef-
fects of metoclopramide on the primary headaches with 
Table 1: Comparison of demographic data between two studied groups 
Variable Acetaminophen Metoclopramide p1 
Age (year)    
<18 7 (43.8) 9 (56.2) <0.001 
18-40 43 (67.2) 21 (32.8)  
41-60 0 (0.0) 18 (100.0)  
61-75 0 (0.0) 2 (100.0)  
Gender    
Male 22 (51.2) 21 (48.8)  
Female 28 (49.1) 29 (50.9) 0.84 
Marital status     
Single 15 (53.6) 13 (46.4) 0.66 
Married 35 (48.6) 37 (51.4)  
Type of headache   
Migraine 35 (67.3) 17 (32.7)  
Tension type 8 (23.5) 26 (76.5) <0.001 
Cluster 7 (50.0) 7 (50.0)  
1, Based on Chi-Squared test; 2, based on Fisher exact test. 
 
 
Table 2: comparison of pain score and successes rate in medical interventions between studied groups 
Time (minute) 
Acetaminophen  Metoclopramide 
p1 
Mean ± SD Success rate (%)  Mean ± SD Success rate (%) 
Baseline 9.4 ± 0.7 ----  9.1 ± 1.3 ---- 0.46 
 15 7.0 ± 1.4 21 (42.0)  9.0 ± 1.3 0 (0.0) <0.001 
30 4.5 ± 2.0 50 (100.0)  6.6 ± 1.5 34 (74.0) <0.001 
60 3.1 ± 2.1 50 (100.0)  5.4 ± 1.6 47 (94.0) <0.001 
120 1.5 ± 1.2 50 (100.0)  3.6 ± 2.0 50 (100.0) <0.001 
1, Based on Kruskal-Wallis equality of populations rank test; SD: Standard deviation. 
 
Table 3: results of multivariate analysis for comparison of success rate between two groups 
Time (minute) Odds ratio 95% CI p1 
15 1.43 1.21-1.73 <0.001 
30 1.38 1.17-1.64 <0.001 
60 1.10 1.01-1.26 0.04 
1, Based on general linear model adjusted for age and type of headache; CI: Confidence interval. 
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different results. While some of them showed good effi-
cacy of metoclopramide for primary headaches, others 
concluded no efficacy. Salazar-Zúñiga and Garfias-Arvizu 
compared metoclopramide and sumatriptan in migraine 
sufferers and demonstrated that metoclopramide is 
more effective (18).  Tec et al. showed that metoclo-
pramide has therapeutic effects on headache, alone (4). 
Coppola et al. compared prochlorperazine, metoclo-
pramide, and placebo; they showed that prochlorpera-
zine has therapeutic effects on headache, but metoclo-
pramide is more effective than placebo (9). In contrast, 
Cameron et al. compared prochlorperazine and metoclo-
pramide, and demonstrated that prochlorperazine and 
metoclopramide are both effective on acute migraine 
headaches (19).  Colman et al. concluded that metoclo-
pramide is effective on the migraine especially in combi-
nation with other agents (20).  Friedman et al. stated that 
a combination of metoclopramide and diphenhydramine 
are more effective than ketorolac for headaches (21).  In 
another study, Friedman et al. compared 10 milligrams 
of IV prochlorperazine and combination of 20 milligrams 
metoclopramide and 25 milligrams diphenhydramine 
for acute migraine headaches. They showed pro-
chlorperazine and combination of metoclopramide and 
diphenhydramine have the same effect for acute mi-
graine headaches (22).  In another study, Friedman et al. 
displayed 10 metoclopramide are more efficient than 30 
milligrams ketorolac or 1000 milligrams valproate so-
dium (23). Weinman et al. performed a systemic review 
to find an effective drug for tension type of headaches 
and reviewed 8 studies. Their results were as below: 
metamizole, chlorpromazine, and metoclopramide are 
more effective than placebo for acute pain. The combina-
tion of metoclopramide with diphenhydramine has su-
periority to ketorolac.  mepivacaine, meperidine with 
promethazine, and sumatriptan are not more effective 
than placebo (24). The results of this study had some 
similarities and dissimilarities with other studies. Vari-
ances in regimens and doses of medications can result in 
different efficacy of medications, so that use of one 
standard regimen may lead to results that are more co-
herent. Extrapyramidal reactions are one of the most im-
portant side effects of metoclopramide, which have been 
reported in nearly 10% of cases. For example, Coppola et 
al. demonstrated 2.5% of patients displayed dystonia or 
akathisia in initial minutes of drug administration (12). 
Also Friedman et al. stated that akathisia developed in 
9.3% of patients (25). However, no side effect was found 
in the present study. There were several limitations in 
this study. The first limitation was the short follow-up 
period. Although, during 2 hours follow up no side effect 
was observed, the longer period such as 1or 2 days and 
even 1week follow up might have provided a better op-
portunity to evaluate long-term side effects and head-
ache recurrence. Another limitation was single-blinded 
design of the trial. We were unable to do the study in a 
double-blinded way, because the routes of administra-
tion for drugs were different. Moreover, the lack of a pla-
cebo group or standard arm due to ethical consideration 
was also considered as another limitation. 
Conclusion: 
The present study demonstrated that efficacy of meto-
clopramide in pain relief of headaches is lower than ac-
etaminophen.  In this regard, success rate of acetamino-
phen in pain relief was 42.0%, while it was 0% for meto-
clopramide within 15 minutes. The efficacy of aceta-
minophen continued until 60 minutes. 
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